X0206 3 2021-07-29 0 0001740279 IN8BIO, INC. INAB 0001813316 Kreis Leslie W. C/O BIOS EQUITY PARTNERS 1751 RIVER RUN, SUITE 400 FORT WORTH TX 76107 0 0 1 0 0001728851 BIOS Fund II NT, LP 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107 0 0 1 0 0001714576 BIOS Fund II, LP 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107 0 0 1 0 0001716869 BIOS Fund II QP, LP 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107 0 0 1 0 0001740029 BIOS Incysus Co-Invest I, LP 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107 0 0 1 0 0001813313 Bios Equity Partners II, LP 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107 0 0 1 0 0001831976 BIOS Equity Partners III, LP 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107 0 0 1 0 0001813270 Cavu Management, LP 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107 0 0 1 0 0001813310 Cavu Advisors, LLC 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107 0 0 1 0 Series A Preferred Stock Common Stock 574432 I See footnote Series A Preferred Stock Common Stock 1876624 I See footnote Series A Preferred Stock Common Stock 251211 I See footnote Series A Preferred Stock Common Stock 997433 I See footnote Series A Preferred Stock Common Stock 340712 I See footnote Series A Preferred Stock Common Stock 2225316 I See footnote Series A Preferred Stock Common Stock 359374 I See footnote Each share of Series A Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, has no expiration date and is expected to automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering. The securities are directly held by Bios Fund II, LP ("Bios Fund II"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. The securities are directly held by Bios Fund II QP. The securities are directly held by Bios Fund II NT. The securities are directly held by BIOS Incysus. The securities are directly held by Bios Fund III. The securities are directly held by Bios Fund III QP. The securities are directly held by Bios Fund III NT. This Form 3 is the first of two Forms 3 filed relating to the same event. The Form 3 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 3 to a maximum of 10 reporting person. The second Form 3 will be filed by Aaron Glenn Louis Fletcher as the designated filer. /s/ Leslie W. Kreis, Jr. 2021-07-29 Bios Fund II NT, LP, By: Bios Equity Partners II, LP, its general partner, By: Cavu Management, LP, its general partner, By: Cavu Advisors, LLC, its general partner, By: /s/ Leslie W. Kreis, Jr., Manager 2021-07-29 Bios Fund II, LP, By: Bios Equity Partners II, LP, its general partner, By: Cavu Management, LP, its general partner, By: Cavu Advisors, LLC, its general partner, By: /s/ Leslie W. Kreis, Jr., Manager 2021-07-29 Bios Fund II QP, LP, By: Bios Equity Partners II, LP, its general partner, By: Cavu Management, LP, its general partner, By: Cavu Advisors, LLC, its general partner, By: /s/ Leslie W. Kreis, Jr., Manager 2021-07-29 BIOS Incysus Co-Invest I, LP, By: Bios Equity Partners II, LP, its general partner, By: Cavu Management, LP, its general partner, By: Cavu Advisors, LLC, its general partner, By: /s/ Leslie W. Kreis, Jr., Manager 2021-07-29 Bios Equity Partners II, LP, By: Cavu Management, LP, its general partner, By: Cavu Advisors, LLC, its general partner, By: /s/ Leslie W. Kreis, Jr., Manager 2021-07-29 Bios Equity Partners III, LP, By: Cavu Management, LP, its general partner, By: Cavu Advisors, LLC, its general partner, By: /s/ Leslie W. Kreis, Jr, Manager 2021-07-29 Cavu Management, LP, By: Cavu Advisors, LLC, its general partner, By: /s/ Leslie W. Kreis, Jr., Manager 2021-07-29 Cavu Advisors, LLC, By: /s/ Leslie W. Kreis, Jr., Manager 2021-07-29